257 related articles for article (PubMed ID: 34858854)
1. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
Front Oncol; 2021; 11():774088. PubMed ID: 34858854
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.
Zilenaite-Petrulaitiene D; Rasmusson A; Besusparis J; Valkiuniene RB; Augulis R; Laurinaviciene A; Plancoulaine B; Petkevicius L; Laurinavicius A
Virchows Arch; 2024 Jan; ():. PubMed ID: 38217716
[TBL] [Abstract][Full Text] [Related]
3. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
Zilenaite D; Rasmusson A; Augulis R; Besusparis J; Laurinaviciene A; Plancoulaine B; Ostapenko V; Laurinavicius A
Front Oncol; 2020; 10():950. PubMed ID: 32612954
[TBL] [Abstract][Full Text] [Related]
4. Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius A; Plancoulaine B; Rasmusson A; Besusparis J; Augulis R; Meskauskas R; Herlin P; Laurinaviciene A; Abdelhadi Muftah AA; Miligy I; Aleskandarany M; Rakha EA; Green AR; Ellis IO
Virchows Arch; 2016 Apr; 468(4):493-502. PubMed ID: 26818835
[TBL] [Abstract][Full Text] [Related]
5. Immuno-Interface Score to Predict Outcome in Colorectal Cancer Independent of Microsatellite Instability Status.
Nestarenkaite A; Fadhil W; Rasmusson A; Susanti S; Hadjimichael E; Laurinaviciene A; Ilyas M; Laurinavicius A
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050344
[TBL] [Abstract][Full Text] [Related]
6. Immunogradient Indicators for Antitumor Response Assessment by Automated Tumor-Stroma Interface Zone Detection.
Rasmusson A; Zilenaite D; Nestarenkaite A; Augulis R; Laurinaviciene A; Ostapenko V; Poskus T; Laurinavicius A
Am J Pathol; 2020 Jun; 190(6):1309-1322. PubMed ID: 32194048
[TBL] [Abstract][Full Text] [Related]
7. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
9. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
10. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
11.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
12. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
Bense RD; Sotiriou C; Piccart-Gebhart MJ; Haanen JBAG; van Vugt MATM; de Vries EGE; Schröder CP; Fehrmann RSN
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27737921
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
Kim HS; Yoo TK; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Apr; 180(2):461-470. PubMed ID: 32020434
[TBL] [Abstract][Full Text] [Related]
14. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
[TBL] [Abstract][Full Text] [Related]
15. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer.
Zhou D; Li M; Yasin MH; Lu Q; Fu J; Jiang K; Hong R; Wang S; Xu F
NPJ Breast Cancer; 2023 Apr; 9(1):30. PubMed ID: 37085500
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
[TBL] [Abstract][Full Text] [Related]
18. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.
Zurawska U; Baribeau DA; Giilck S; Victor C; Gandhi S; Florescu A; Verma S
Curr Oncol; 2013 Dec; 20(6):e539-45. PubMed ID: 24311954
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
